Entrada Therapeutics (TRDA) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Does the MarketBeat Community favor OCUL or TRDA?

Ocular Therapeutix received 421 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.62% of users gave Entrada Therapeutics an outperform vote while only 70.32% of users gave Ocular Therapeutix an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 443 70.32%	Underperform Votes 187 29.68%
Entrada Therapeutics	Outperform Votes 22 84.62%	Underperform Votes 4 15.38%

Which has better earnings and valuation, OCUL or TRDA?

Entrada Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$59.65M	19.50	-$80.74M	-$1.15	-6.35
Entrada Therapeutics	$172.22M	1.70	-$6.68M	$0.81	9.51

Do analysts recommend OCUL or TRDA?

Ocular Therapeutix currently has a consensus price target of $16.25, suggesting a potential upside of 122.60%. Entrada Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 233.33%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Entrada Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the media favor OCUL or TRDA?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 9 articles in the media. Ocular Therapeutix's average media sentiment score of 1.59 beat Entrada Therapeutics' score of 0.61 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Entrada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in OCUL or TRDA?

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is OCUL or TRDA more profitable?

Entrada Therapeutics has a net margin of 25.53% compared to Ocular Therapeutix's net margin of -283.74%. Entrada Therapeutics' return on equity of 16.11% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Entrada Therapeutics	25.53%	16.11%	10.39%

Which has more risk and volatility, OCUL or TRDA?

Ocular Therapeutix has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500.

Summary

Entrada Therapeutics beats Ocular Therapeutix on 13 of the 18 factors compared between the two stocks.